Random-forest metabolite profiling reduces false-positive newborn screens for four inherited disorders
A 121-analyte LC–MS/MS panel combined established markers, untargeted-metabolomics features and chromatographically resolved isobars with random-forest classification of California newborn-screen dried blood spots. In 883 archived infant samples, the study reports that the second-tier approach maintained 100% sensitivity while reducing false positives by 83% for glutaric acidemia type I, 84% for methylmalonic acidemia, 100% for ornithine transcarbamylase deficiency and 51% for very-long-chain acyl-CoA dehydrogenase deficiency. Several long-chain acylcarnitine and hydroxy-acylcarnitine isobar features contributed to classification, although their chemical identities were unresolved.
Technology: Random Forest classifier trained on targeted LC–MS/MS metabolite profiles
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In 883 archived infant samples, the study reports that the second-tier approach maintained 100% sensitivity while reducing false positives by 83% for glutaric acidemia type I, 84% for methylmalonic acidemia, 100% for ornithine transcarbamylase deficiency and 51% for very-long-chain acyl-CoA dehydrogenase deficiency.
- Still unknown: This was a proof-of-principle second-tier simulation on residual archived California newborn-screen specimens, not a prospective implementation study. The validation sample was not a fully independent external set, and archived-sample degradation and processing batch effects limited biomarker discovery; some discriminating isobar identities and biological significance remain unknown. The reported sensitivity and false-positive reductions are cohort-specific and do not establish improved health outcomes or routine clinical utility.
- AI role: The classifier modeled multianalyte profiles from true-positive and false-positive screen-positive samples to distinguish the groups for four inherited metabolic disorders. Feature-importance analysis showed that complex profiles, including unresolved long-chain acylcarnitine/hydroxy-acylcarnitine isobars, contributed to classification; the model's second-tier performance was assessed against known case status.
Evidence sources: https://onlinelibrary.wiley.com/doi/full/10.1002/jimd.12591
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 23 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.